Place of the novel drug ranolazine in the treatment of coronary artery disease
Despite the widely used myocardial revascularization (angioplasty and stenting, aorto- or mammo-coronary bypass), extensive pharmacotherapy aimed at improving the quality of life (through the improvement of exercise tolerance and elimination of angina attacks) and increasing its "quantity"...
Gespeichert in:
Veröffentlicht in: | Medicinskij sovet 2014-12 (12), p.44-48 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | rus |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Despite the widely used myocardial revascularization (angioplasty and stenting, aorto- or mammo-coronary bypass), extensive pharmacotherapy aimed at improving the quality of life (through the improvement of exercise tolerance and elimination of angina attacks) and increasing its "quantity", i.e. improving the prognosis, coronary heart disease remains the leading cause of overall mortality in the world and in Russia. In a majority of patients, angina persists even after revascularization of the myocardium, therefore they still need antianginal therapy. [1] Additionally, for some patients revascularization is not possible because of anatomical features of coronary vessels and contraindications to medicines traditionally used in angioplasty. |
---|---|
ISSN: | 2079-701X 2658-5790 |